Abstract
Atrial fibrillation (AF) is a common arrhythmia that has major morbidity and mortality. Hypoxia plays an important role in AF initiation and maintenance. Hypoxia-inducible factor (HIF), the master regulator of oxygen homeostasis in cells, plays a fundamental role in the regulation of multiple chemokines and cytokines that are involved in different physiological and pathophysiological pathways. HIF is also involved in the pathophysiology of AF induction and propagation mostly through structural remodeling such as fibrosis; however, some of the cytokines discussed have even been implicated in electrical remodeling of the atria. In this article, we highlight the association between HIF and some of its related cytokines with AF. Additionally, we provide an overview of the potential diagnostic benefits of using the mentioned cytokines as AF biomarkers. Research discussed in this review suggests that the expression of these cytokines may correlate with patients who are at an increased risk of developing AF. Furthermore, cytokines that are elevated in patients with AF can assist clinicians in the diagnosis of suspect paroxysmal AF patients. Interestingly, some of the cytokines have been elevated specifically when AF is associated with a hypercoagulable state, suggesting that they could be helpful in the clinician’s and patient’s decision to begin anticoagulation. Finally, more recent research has demonstrated the promise of targeting these cytokines for the treatment of AF. While still in its early stages, tools such as neutralizing antibodies have proved to be efficacious in targeting the HIF pathway and treating or preventing AF.
Similar content being viewed by others
References
Patel NJ, Deshmukh A, Pant S et al (2014) Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 Through 2010. Circulation 129:2371–2379. https://doi.org/10.1161/circulationaha.114.008201
Nattel S, Harada M (2014) Atrial remodeling and atrial fibrillation. J Am Coll Cardiol 63:2335–2345. https://doi.org/10.1016/j.jacc.2014.02.555
Wakili R, Voigt N, Kääb S et al (2011) Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Investig 121:2955–2968
Nattel S, Dobrev D (2012) The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 33:1870–1877
Shinagawa K, Shi Y-F, Tardif J-C et al (2002) Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 105:2672–2678. https://doi.org/10.1161/01.cir.0000016826.62813.f5
Pei J-M, Kravtsov GM, Wu S et al (2003) Calcium homeostasis in rat cardiomyocytes during chronic hypoxia: a time course study. Am J Physiol Physiol 285:C1420–C1428. https://doi.org/10.1152/ajpcell.00534.2002
Gemel J, Su Z, Gileles-Hillel A et al (2017) Intermittent hypoxia causes NOX2-dependent remodeling of atrial connexins. BMC Cell Biol 18:7. https://doi.org/10.1186/s12860-016-0117-5
Su F, Zhang W, Chen Y et al (2014) Significance of hypoxia-inducible factor-1α expression with atrial fibrosis in rats induced with isoproterenol. Exp Ther Med 8:1677–1682. https://doi.org/10.3892/etm.2014.1989
Dimitri H, Ng M, Brooks AG et al (2012) Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm 9:321–327. https://doi.org/10.1016/j.hrthm.2011.10.017
White CW, Kerber RE, Weiss HR, Marcus ML (1982) The effects of atrial fibrillation on atrial pressure-volume and flow relationships. Circ Res 51:205–215. https://doi.org/10.1161/01.res.51.2.205
Lammers WJ, Kirchhof C, Bonke FI, Allessie MA (1992) Vulnerability of rabbit atrium to reentry by hypoxia. Role of inhomogeneity in conduction and wavelength. Am J Physiol Circ Physiol 262:H47–H55. https://doi.org/10.1152/ajpheart.1992.262.1.h47
Todd K, McIntyre WF, Baranchuk A (2010) Obstructive sleep apnea and atrial fibrillation. Nat Sci Sleep 2:39–45. https://doi.org/10.2147/nss.s7625
Channaveerappa D, Lux JC, Wormwood KL et al (2017) Atrial electrophysiological and molecular remodelling induced by obstructive sleep apnoea. J Cell Mol Med 21:2223–2235. https://doi.org/10.1111/jcmm.13145
Gramley F, Lorenzen J, Pezzella F et al (2009) Hypoxia and myocardial remodeling in human cardiac allografts: a time-course study. J Heart Lung Transplant 28:1119–1126. https://doi.org/10.1016/j.healun.2009.05.038
Colucci WS (1987) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L–25L. https://doi.org/10.1016/s0002-9149(97)00845-x
De BR, Pinto Y, Van VD (2003) The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10:113–126. https://doi.org/10.1080/713773607
Sinno H, Derakhchan K, Libersan D et al (2003) Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107:1930–1936. https://doi.org/10.1161/01.cir.0000058743.15215.03
Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007:cm8–cm8. https://doi.org/10.1126/stke.4072007cm8
Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148:399–408. https://doi.org/10.1016/j.cell.2012.01.021
Semenza GL (2014) Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 76:39–56. https://doi.org/10.1146/annurev-physiol-021113-170322
Thijssen VL, Van der Velden HM, Van Ankeren EP (2002) Analysis of altered gene expression during sustained atrial fibrillation in the goat. Cardiovasc Res 54:427–437. https://doi.org/10.1016/s0008-6363(02)00260-2
Gramley F, Lorenzen J, Jedamzik B et al (2010) Atrial fibrillation is associated with cardiac hypoxia. Cardiovasc Pathol 19:102–111. https://doi.org/10.1016/j.carpath.2008.11.001
Martinez C-A, Kerr B, Jin C et al (2019) Obstructive sleep apnea activates HIF-1 in a hypoxia dose-dependent manner in HCT116 colorectal carcinoma cells. Int J Mol Sci 20:445. https://doi.org/10.3390/ijms20020445
Ogi H, Nakano Y, Niida S et al (2010) Is structural remodeling of fibrillated atria the consequence of tissue hypoxia? Circ J 74:1815–1821. https://doi.org/10.1253/circj.cj-09-0969
Abe I, Teshima Y, Kondo H et al (2018) Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm 15:1717–1727. https://doi.org/10.1016/j.hrthm.2018.06.025
Xu Y, Sharma D, Du F, Liu Y (2013) The role of Toll-like receptor 2 and hypoxia-induced transcription factor-1α in the atrial structural remodeling of non-valvular atrial fibrillation. Int J Cardiol 168:2940–2941. https://doi.org/10.1016/j.ijcard.2013.03.174
Dengler VL, Galbraith MD, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49:1–15. https://doi.org/10.3109/10409238.2013.838205
Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732. https://doi.org/10.1038/nrc1187
Ferrara N, Houck K, Jakeman LY, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32. https://doi.org/10.1210/edrv-13-1-18
Stuttfeld E, Ballmer-Hofer K (2009) Structure and function of VEGF receptors. IUBMB Life 61:915–922. https://doi.org/10.1002/iub.234
Forsythe JA, Jiang BH, Iyer NV et al (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613. https://doi.org/10.1128/mcb.16.9.4604
Berntsson J, Smith JG, Johnson LSB et al (2019) Increased vascular endothelial growth factor D is associated with atrial fibrillation and ischaemic stroke. Heart 105:553–558. https://doi.org/10.1136/heartjnl-2018-313684
Iwasaki Y, Yamashita T, Sekiguchi A et al (2016) Importance of pulmonary vein preferential fibrosis for atrial fibrillation promotion in hypertensive rat hearts. Can J Cardiol 32:767–776. https://doi.org/10.1016/j.cjca.2015.09.006
Yao C, Veleva T, Scott L et al (2018) Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation 138:2227–2242. https://doi.org/10.1161/circulationaha.118.035202
Li J, Solus J, Chen Q et al (2010) Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 7:438–444. https://doi.org/10.1016/j.hrthm.2009.12.009
Scridon A, Morel E, Nonin-Babary E et al (2012) Increased intracardiac vascular endothelial growth factor levels in patients with paroxysmal, but not persistent atrial fibrillation. Europace 14:948–953. https://doi.org/10.1093/europace/eur418
Kim CH, Cho YS, Chun YS et al (2002) Early expression of myocardial HIF-1α in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res. https://doi.org/10.1161/hh0202.104923
Li J, Hampton T, Morgan JP, Simons M (1997) Stretch-induced VEGF expression in the heart. J Clin Investig 100:18–24. https://doi.org/10.1172/JCI119510
Seko Y, Seko Y, Takahashi N et al (1999) Pulsatile stretch stimulates vascular endothelial growth factor (VEGF) secretion by cultured rat cardiac myocytes. Biochem Biophys Res Commun 254:462–465. https://doi.org/10.1006/bbrc.1998.9969
Seko Y, Nishimura H, Takahashi N et al (2000) Serum levels of vascular endothelial growth factor and transforming growth factor-b1 in patients with atrial fibrillation undergoing defibrillation therapy. Jpn Heart J 41:27–32. https://doi.org/10.1536/jhj.41.27
Jong AM, Maass AH, Oberdorf-Maass SU et al (2013) Cyclical stretch induces structural changes in atrial myocytes. J Cell Mol Med 17:743–753. https://doi.org/10.1111/jcmm.12064
Granier M, Massin F, Pasquie J-L (2013) Pro- and anti-arrhythmic effects of anti-inflammatory drugs. Anti-Inflamm Antiallergy Agents Med Chem 12:83–93. https://doi.org/10.2174/1871523011312010010
Serban RC, Balan AI, Perian M (2019) Atrial electrical remodeling induced by chronic ischemia and inflammation in patients with stable coronary artery disease. Chin J Physiol 62(1):11–16. https://doi.org/10.4103/CJP.CJP_2_19
Mezache L, Struckman H, Greer-Short A et al (2019) Vegf-induced vascular leak promotes atrial fibrillation by disrupting intercalated disc nanodomains. Biophys J 116:32a. https://doi.org/10.1016/j.bpj.2018.11.212
Choudhury A, Freestone B, Patel J, Lip GYH (2007) Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and tissue factor in atrial fibrillation. Chest 132:1913–1919. https://doi.org/10.1378/chest.07-1565
Chung NAY, Belgore F, Li-Saw-Hee FL et al (2002) Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 33:2187–2191. https://doi.org/10.1161/01.str.0000023889.84649.3d
Freestone B, Chong AY, Lim HS et al (2005) Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis? Ann Med 37:365–372. https://doi.org/10.1080/07853890510037392
Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227:493–507. https://doi.org/10.1002/jcp.22783
Kietzmann T, Jungermann K, Görlach A (2003) Regulation of the hypoxia-dependent plasminogen activator inhibitor 1 expression by MAP kinases. Thromb Haemost 89(4):666–673. https://doi.org/10.1055/s-0037-1613573
Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66:6264–6270. https://doi.org/10.1158/0008-5472.can-05-2519
De WRR, Marcos EG, Dudink EAMP et al (2019) Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. Europace 22:352–360. https://doi.org/10.1093/europace/euz339
Negreva M, Georgiev S, Vitlianova K (2016) Early effects of paroxysmal atrial fibrillation on plasma markers of fibrinolysis. Medicine (Baltimore) 95:e5184–e5184. https://doi.org/10.1097/MD.0000000000005184
Gramley F, Lorenzen J, Plisiene J et al (2007) Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc Electrophysiol 18:1076–1082. https://doi.org/10.1111/j.1540-8167.2007.00906.x
Pretorius M, Donahue BS, Yu C et al (2007) Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 116:I-1–I-7. https://doi.org/10.1161/circulationaha.106.677906
Tveit A, Seljeflot I, Grundvold I et al (2008) Levels of PAI-1 and outcome after electrical cardioversion for atrial fibrillation. Thromb Res 121:447–453. https://doi.org/10.1016/j.thromres.2007.06.014
Mulder BA, Geelhoed B, van der Harst P et al (2018) Plasminogen activator inhibitor-1 and tissue plasminogen activator and incident AF: data from the PREVEND study. Int J Cardiol 272:208–210. https://doi.org/10.1016/j.ijcard.2018.08.029
Mondillo S, Sabatini L, Agricola E et al (2000) Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. Int J Cardiol 75:227–232. https://doi.org/10.1016/s0167-5273(00)00336-3
Otto A, Fareed J, Liles J et al (2018) Fibrinolytic deficit and platelet activation in atrial fibrillation and their postablation modulation. Clin Appl Thromb Hemost 24:803–807. https://doi.org/10.1177/1076029617750270
Liles J, Liles J, Wanderling C et al (2016) Increased level of thrombotic biomarkers in patients with atrial fibrillation despite traditional and new anticoagulant therapy. Clin Appl Thromb Hemost 22:743–748. https://doi.org/10.1177/1076029616648407
Berge T, Ulimoen SR, Enger S et al (2013) Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly. Scand J Clin Lab Investig 73:326–333. https://doi.org/10.3109/00365513.2013.780093
Han W, Li WM, Song LY et al (2005) The experimental study on changes of endothelial nitric oxide synthase and plasminogen activator inhibitor-1 protein in the canine atrial fibrillation model. Zhonghua xin xue guan bing za zhi 33(1):69–72
Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312. https://doi.org/10.1101/gad.1653708
Schultz K, Fanburg BL, Beasley D (2006) Hypoxia and hypoxia-inducible factor-1α promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Circ Physiol 290:H2528–H2534. https://doi.org/10.1152/ajpheart.01077.2005
Chen Y, Surinkaew S, Naud P et al (2017) JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate. Cardiovasc Res 113:310–320. https://doi.org/10.1093/cvr/cvx004
Pontén A, Folestad EB, Pietras K, Eriksson U (2005) Platelet-derived growth factor D induces cardiac fibrosis and proliferation of vascular smooth muscle cells in heart-specific transgenic mice. Circ Res 97:1036–1045. https://doi.org/10.1161/01.res.0000190590.31545.d4
Pontén A, Li X, Thorén P et al (2003) Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am J Pathol 163:673–682. https://doi.org/10.1016/S0002-9440(10)63694-2
Tuuminen R, Nykänen AI, Krebs R et al (2009) PDGF-A, -C, and -D but not PDGF-B increase TGF-β1 and chronic rejection in rat cardiac allografts. Arterioscler Thromb Vasc Biol 29:691–698. https://doi.org/10.1161/atvbaha.108.178558
Yang D, Yuan J, Liu G et al (2013) Angiotensin receptor blockers and statins could alleviate atrial fibrosis via regulating platelet-derived growth factor/Rac1/nuclear factor-kappa B axis. Int J Med Sci 10:812–824. https://doi.org/10.7150/ijms.5931
Babapoor-Farrokhran S, Rasekhi RT, Gill D et al (2020) How transforming growth factor contributes to atrial fibrillation? Life Sci 266:118823. https://doi.org/10.1016/j.lfs.2020.118823
Jiang Z, Zhong G, Wen L et al (2016) The role of platelet-derived growth factor-B/platelet-derived growth factor receptor-β signaling in chronic atrial fibrillation. Cardiology 133:242–256. https://doi.org/10.1159/000442940
Fiset C (2013) Platelet-derived growth factor: a promising therapeutic target for atrial fibrillation. Heart Rhythm 10:1052–1053. https://doi.org/10.1016/j.hrthm.2013.04.003
Musa H, Kaur K, O’Connell R et al (2013) Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. Heart Rhythm 10:1044–1051. https://doi.org/10.1016/j.hrthm.2013.03.014
Feldser D, Agani F, Iyer NV et al (1999) Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59(16):3915–3918
Lee W-S, Kim J (2018) Insulin-like growth factor-1 signaling in cardiac aging. Biochim Biophys Acta Mol Basis Dis 1864:1931–1938. https://doi.org/10.1016/j.bbadis.2017.08.029
Busch M, Krüger A, Gross S et al (2019) Relation of IGF-1 and IGFBP-3 with prevalent and incident atrial fibrillation in a population-based study. Heart Rhythm 16:1314–1319. https://doi.org/10.1016/j.hrthm.2019.03.017
Polovina M, Lip G, Potpara T (2014) Endothelial (dys)function in lone atrial fibrillation. Curr Pharm Des 21:622–645. https://doi.org/10.2174/1381612820666140825143028
Troncoso R, Ibarra C, Vicencio JM et al (2014) New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab 25:128–137. https://doi.org/10.1016/j.tem.2013.12.002
Ittermann T, van Noord C, Friedrich N et al (2012) The association between insulin-like growth factor-I and cardiac repolarization. Growth Horm IGF Res 22:1–5. https://doi.org/10.1016/j.ghir.2011.11.001
González-Guerra JL, Castilla-Cortazar I, Aguirre GA et al (2017) Partial IGF-1 deficiency is sufficient to reduce heart contractibility, angiotensin II sensibility, and alter gene expression of structural and functional cardiac proteins. PLoS One 12:e0181760–e0181760. https://doi.org/10.1371/journal.pone.0181760
Wang J, Li Z, Du J et al (2019) The expression profile analysis of atrial mRNA in rats with atrial fibrillation: the role of IGF1 in atrial fibrosis. BMC Cardiovasc Disord 19:40. https://doi.org/10.1186/s12872-019-1013-7
Babapoor-Farrokhran S, Gill D, Rasekhi RT (2020) The role of long noncoding RNAs in atrial fibrillation. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2020.01.015
Sirish P, Li N, Timofeyev V et al (2016) Molecular mechanisms and new treatment paradigm for atrial fibrillation. Circ Arrhythm Electrophysiol. https://doi.org/10.1161/CIRCEP.115.003721e003721.10.1161/CIRCEP.115.003721
Wang K, Liu Y, Huang S et al (2019) Does an imbalance in circulating vascular endothelial growth factors (VEGFs) cause atrial fibrillation in patients with valvular heart disease? J Thorac Dis 11:5509–5516. https://doi.org/10.21037/jtd.2019.11.32
Woitek F, Zentilin L, Hoffman NE et al (2015) Intracoronary cytoprotective gene therapy. J Am Coll Cardiol 66:139–153. https://doi.org/10.1016/j.jacc.2015.04.071
Pepe M, Mamdani M, Zentilin L et al (2010) Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 106:1893–1903. https://doi.org/10.1161/CIRCRESAHA.110.220855
Tofler GH, Massaro J, O’Donnell CJ et al (2016) Plasminogen activator inhibitor and the risk of cardiovascular disease: the Framingham Heart Study. Thromb Res 140:30–35. https://doi.org/10.1016/j.thromres.2016.02.002
Acknowledgements
The authors are grateful to our colleagues, who contributed invaluable clinical information.
Funding
This research did not receive any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Babapoor-Farrokhran, S., Gill, D., Alzubi, J. et al. Atrial fibrillation: the role of hypoxia-inducible factor-1-regulated cytokines. Mol Cell Biochem 476, 2283–2293 (2021). https://doi.org/10.1007/s11010-021-04082-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-021-04082-9